Proxy statement

RRD Provides an Update on the Unsolicited Non-Binding Proposal From the “Strategic Party” to Acquire RRD

Retrieved on: 
Thursday, January 20, 2022 - 2:22pm

On January 3, 2022, the Strategic Party had indicated to RRD that it was targeting January 21, 2022 for a submission of a binding proposal.

Key Points: 
  • On January 3, 2022, the Strategic Party had indicated to RRD that it was targeting January 21, 2022 for a submission of a binding proposal.
  • In lieu of submitting a binding proposal, the Strategic Party delivered the non-binding Updated Strategic Party Proposal, which provides for the following, among other terms and conditions:
    Value: Increases the offered price to $11.50 per share in cash.
  • Due Diligence: States that the Strategic Party has substantially completed its financial, legal, tax and other due diligence on RRD and its business.
  • Non-Binding and Conditional: The Updated Strategic Party Proposal remains non-binding and subject to certain terms and conditions.

RRD Announces Commencement of Consent Solicitations for Its Outstanding Debt Securities

Retrieved on: 
Thursday, January 20, 2022 - 2:22pm

The Consent Solicitations are subject to the terms and conditions set forth in the consent solicitation statement, dated January 20, 2022 (the Consent Solicitation Statement), which is being distributed to Holders of the Debt Securities.

Key Points: 
  • The Consent Solicitations are subject to the terms and conditions set forth in the consent solicitation statement, dated January 20, 2022 (the Consent Solicitation Statement), which is being distributed to Holders of the Debt Securities.
  • Payment of the Consent Consideration (if applicable) for the Debt Securities is conditioned upon the receipt by the Company of the Consents of a majority in aggregate principal amount of the outstanding Debt Securities, other than Debt Securities beneficially owned by the Company or any of its affiliates (the Requisite Consents).
  • If the Consent Solicitation with respect to one or more series of Debt Securities is terminated or the Company does not receive the Requisite Consent for one or more series of Debt Securities, the Proposed Amendments will have no effect on the applicable Indenture, such series of Debt Securities or the Holders of such Debt Securities.
  • The Consent Solicitations are not being made to, and Consents are not being solicited from, Holders of Debt Securities in any jurisdiction in which it is unlawful to make such Consent Solicitations or grant such consent.

SCVX Signs Letter of Intent for a Business Combination

Retrieved on: 
Thursday, January 20, 2022 - 1:00pm

SCVX Corp. (SCVX), a publicly traded Special Purpose Acquisition Company (SPAC), has announced today that it has entered into a non-binding letter of intent (LOI) for a business combination.

Key Points: 
  • SCVX Corp. (SCVX), a publicly traded Special Purpose Acquisition Company (SPAC), has announced today that it has entered into a non-binding letter of intent (LOI) for a business combination.
  • SCVX expects to announce additional details regarding the proposed business combination when a definitive agreement is executed, which is expected later in Q12022 and with a closing anticipated in Q32022.
  • SCVX Corp. (SCVX; NYSE: SCVX) is a Special Purpose Acquisition Company (SPAC) seeking to partner with and acquire world class companies.
  • However, while SCVX may elect to update these forward-looking statements at some point in the future, SCVX specifically disclaims any obligation to do so.

NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders

Retrieved on: 
Thursday, January 20, 2022 - 11:50am

Accordingly, the Special Meeting of Stockholders was further adjourned on Proposal Two and will reconvene virtually on January 31, 2022 at 11:00 a.m. Pacific time at http://www.virtualshareholdermeeting.com/NBY2021SM .

Key Points: 
  • Accordingly, the Special Meeting of Stockholders was further adjourned on Proposal Two and will reconvene virtually on January 31, 2022 at 11:00 a.m. Pacific time at http://www.virtualshareholdermeeting.com/NBY2021SM .
  • The Board of Directors believes that increasing the authorized common stock is in the best interests of NovaBay and its stockholders.
  • All other proposals voted on during the Special Meeting of Stockholders were passed at the December 17, 2021 meeting.
  • Stockholders who have previously submitted their proxy or otherwise voted on Proposal Two at the Special Meeting of Stockholders and who do not want to change their vote need not take any action.

Ensysce Biosciences Reminds Stockholders to Vote at Upcoming Special Meeting

Retrieved on: 
Wednesday, January 19, 2022 - 9:19pm

Questions and answers pertaining to the upcoming meeting are included below:

Key Points: 
  • Questions and answers pertaining to the upcoming meeting are included below:
    What is the purpose of the Special Meeting?
  • At the Special Meeting, the stockholders will act upon the matters outlined in the Notice of Special Meeting of Stockholders.
  • Due to health concerns stemming from the COVID-19 pandemic, the Special Meeting will be a virtual meeting.
  • You will receive an e-mail prior to the meeting with a link and instructions for entering the Special Meeting.

Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders on January 18, 2022

Retrieved on: 
Tuesday, January 18, 2022 - 9:01pm

DUBLIN, Ireland and FORT WASHINGTON, Pa., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it adjourned, without conducting any business, its extraordinary general meeting of shareholders (EGM) on January 18, 2022 to allow the Company to solicit from its shareholders the additional proxies necessary to obtain approval of the proposal described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on November 22, 2021 (Proxy Statement). The EGM will reconvene on Thursday, March 24, 2022, beginning at 5:00 p.m. Irish time (12:00 p.m., U.S. Eastern Time) at 25-28 North Wall Quay, Dublin 1, Ireland.

Key Points: 
  • Nabriva Therapeutics is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.
  • In addition, the forward-looking statements included in this press release represent Nabriva Therapeutics views as of the date of this press release.
  • However, while Nabriva Therapeutics may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.
  • These forward-looking statements should not be relied upon as representing Nabriva Therapeutics views as of any date subsequent to the date of this press release.

InfiniteWorld to Participate in BTIG Metaverse Unbound Conference

Retrieved on: 
Friday, January 14, 2022 - 9:31pm

If you would like to schedule a meeting with Infinites management team please contact your BTIG representative.

Key Points: 
  • If you would like to schedule a meeting with Infinites management team please contact your BTIG representative.
  • www.btig.com
    On December 13, 2021, InfiniteWorld and Aries entered into a definitive agreement for a business combination (the Business Combination) that upon consummation is expected to result in InfiniteWorld becoming a publicly traded company.
  • At InfiniteWorld, we help brands and creators increase engagement, traceability and authenticity for real world and virtual products, events, and interactive experiences.
  • With InfiniteWorld's own NFT marketplace, NFC tags authenticity technology, white-label NFT marketplace solution, and NFT utility tools, InfiniteWorld is the go-to place for brands and creators venturing into the Metaverse!

Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders

Retrieved on: 
Friday, January 14, 2022 - 9:01pm

DUBLIN, Ireland and FORT WASHINGTON, Pa., Jan. 14, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it adjourned, without conducting any business, its extraordinary general meeting of shareholders (EGM) on January 14, 2022 to allow the Company to solicit from its shareholders the additional proxies necessary to obtain approval of the proposal described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on November 22, 2021 (Proxy Statement). The EGM will reconvene on Tuesday, January 18, 2022, beginning at 7:00 p.m. Irish time (2:00 p.m., U.S. Eastern Time) at 25-28 North Wall Quay, Dublin 1, Ireland.

Key Points: 
  • Nabriva Therapeutics is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.
  • In addition, the forward-looking statements included in this press release represent Nabriva Therapeutics views as of the date of this press release.
  • However, while Nabriva Therapeutics may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.
  • These forward-looking statements should not be relied upon as representing Nabriva Therapeutics views as of any date subsequent to the date of this press release.

ENVI and GreenLight Biosciences Announce Filing of Definitive Proxy Statement/Prospectus and the February 1st, 2022 Special Meeting to Approve Proposed Business Combination

Retrieved on: 
Friday, January 14, 2022 - 3:30pm

The Special Meeting to approve the proposed business combination and related matters is scheduled to be held on February 1st, 2022 at 9:00 A.M. Eastern time.

Key Points: 
  • The Special Meeting to approve the proposed business combination and related matters is scheduled to be held on February 1st, 2022 at 9:00 A.M. Eastern time.
  • The Special Meeting will be conducted completely virtually, and can be accessed via live webcast at www.virtualshareholdermeeting.com/ENVI2022SM .
  • For more information, visit https://www.greenlightbiosciences.com/
    In August 2021, GreenLight Biosciences announced plans to become publicly listed through a business combination with Environmental Impact Acquisition Corp. (Nasdaq: ENVI).
  • Private Securities Litigation Reform Act of 1995, with respect to the proposed transaction between GreenLight Biosciences, Inc. ("GreenLight") and Environmental Impact Acquisition Corp. ("ENVI").

Griffon Corporation Announces HSR Clearance for the Acquisition of Hunter and Schedules Conference Call to Discuss First Quarter 2022 Financial Results

Retrieved on: 
Thursday, January 13, 2022 - 11:55am

In addition, Griffon announced that it will release the Companys fiscal first quarter results on Tuesday, Feb 1, 2022, followed by a conference call at 8:30 AM ET.

Key Points: 
  • In addition, Griffon announced that it will release the Companys fiscal first quarter results on Tuesday, Feb 1, 2022, followed by a conference call at 8:30 AM ET.
  • During the call, the Company will provide updated full year fiscal 2022 guidance to reflect the addition of Hunter for part of Griffons 2022 fiscal year.
  • Callers should ask to be connected to the Griffon Corporation teleconference or provide conference ID number 13726303.
  • Griffon provides direction and assistance to its subsidiaries in connection with acquisition and growth opportunities as well as divestitures.